Get started
Author

Anant Madabhushi

Spatial transcriptomics-guided pathology biomarker as a predictor of benefit of adjuvant docetaxel in high-risk localized prostate cancer: NRG/RTOG 0521 (NCT00288080).
2026 · Md Mamunur Rahaman, Amritpal Singh, et al. · Journal of Clinical Oncology · 1
Spatial transcriptomics–guided computational pathology model to stratify docetaxel benefit in metastatic hormone-sensitive prostate cancer: CHAARTED trial (ECOG-ACRIN E3805).
2026 · Md Mamunur Rahaman, Sebastian R. Medina, et al. · Journal of Clinical Oncology · 1
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
2026 · Weisi Xie, Nicholas P. Reder, et al.
AI-derived CD8⁺ cytotoxic T-cell immune signatures from baseline H&E images to predict immunotherapy benefit over chemotherapy in non–small cell lung cancer: Blinded validation in CheckMate-227 (CM227).
2026 · Cristian Barrera, Wiem Safta, et al. · Journal of Clinical Oncology
Baseline CT-derived QVT score as predictor of bevacizumab benefit in advanced non-squamous NSCLC: A retrospective biomarker analysis of SWOG S0819.
2026 · Kai Zhang, Pushkar Mutha, et al. · Journal of Clinical Oncology
CT-derived visceral fat phenotypes to reveal a metabolically defined TOFI subgroup in a lung cancer screening cohort: An imaging-based framework for evaluating the BMI paradox.
2026 · Taofik Ahmed Suleiman, Hilmi Al-Shakhshir, et al. · Journal of Clinical Oncology
PDF
An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).
2026 · Sebastian R. Medina, Naoto Tokuyama, et al. · Journal of Clinical Oncology
AI-driven H&E plasma cell to predict pathological complete response in IO-treated triple-negative breast cancer (Yale; NCT02489448).
2026 · Amritpal Singh, Arpit Aggarwal, et al. · Journal of Clinical Oncology
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
2026 · Weisi Xie, Nicholas P. Reder, et al.
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
2026 · Weisi Xie, Nicholas P. Reder, et al.
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
2026 · Weisi Xie, Nicholas P. Reder, et al.
Computational pathology features of immune architecture predict clinically relevant outcomes in small-cell lung cancer (SCLC)
2026 · Cristian Barrera, Prantesh Jain, et al. · npj Precision Oncology
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
2026 · Weisi Xie, Nicholas P. Reder, et al.
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
2026 · Weisi Xie, Nicholas P. Reder, et al.
Supplementary Information from Prostate Cancer Risk Stratification via Nondestructive 3D Pathology with Deep Learning–Assisted Gland Analysis
2026 · Weisi Xie, Nicholas P. Reder, et al.
Supplementary Figure S3 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026 · Sebastian Medina, Naoto Tokuyama, et al.
Supplementary Figure S14 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026 · Sebastian Medina, Naoto Tokuyama, et al.
Supplementary Figure S9 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026 · Sebastian Medina, Naoto Tokuyama, et al.
Data from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026 · Sebastian Medina, Naoto Tokuyama, et al.
Supplementary Table S5 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026 · Sebastian Medina, Naoto Tokuyama, et al.
Supplementary Figure S10 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026 · Sebastian Medina, Naoto Tokuyama, et al.
Supplementary Figure S12 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026 · Sebastian Medina, Naoto Tokuyama, et al.
Supplementary Figure S8 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026 · Sebastian Medina, Naoto Tokuyama, et al.
Supplementary Figure S5 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026 · Sebastian Medina, Naoto Tokuyama, et al.
Supplementary Figure S11 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026 · Sebastian Medina, Naoto Tokuyama, et al.
Works count: 38
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type